Background: Current consensus guidelines suggest direct oral anticoagulants (DOACs) are interrupted periprocedurally for catheter ablation (CA) of atrial fibrillation (AF). However, this may predispose patients to thromboembolic complications. This study investigates the safety of CA for AF on uninterrupted DOACs compared to uninterrupted warfarin.
INTRODUCTION
Catheter ablation (CA) has emerged as an effective therapeutic option for patients with atrial fibrillation (AF). 1 However, it is associated with low but serious risks including thromboembolic and bleeding complications. Periprocedural management of anticoagulation is critical to minimize these risks. 1 Vitamin K antagonists (VKAs) like warfarin have traditionally been used to prevent procedure-related thromboembolism. Uninterrupted anticoagulation with warfarin during the periprocedural phase is associated with a lower thromboembolic and bleeding risk than cessation of warfarin and bridging with low-molecular-weight heparin (LMWH). 2 However, obtaining optimal therapeutic international normalized ratio (INR) throughout the perioperative period remains a challenge. 2 Subtherapeutic INRs may increase thromboembolic risk whereas supratherapeutic INRs may result in procedural cancellations or increased risk of vascular complications.
Direct oral anticoagulants (DOACs) are an attractive alternative in this setting as they provide various advantages over warfarin while having an equal or better safety profile than warfarin for systemic anticoagulation in nonvalvular AF. 3, 4 However, clinical evidence for use of DOACs in the setting of AF ablation is limited. Current consensus guidelines advocate that DOACs be discontinued 2 days prior to CA due to increased bleeding risk. 5 Available clinical evidence is predominantly from studies wherein the DOAC has been stopped prior to the procedure [6] [7] [8] [9] and hence potentially predisposing patients to the risk of thromboembolic complications. More recently, two randomized controlled trials (RCTs) have demonstrated that the use of uninterrupted dabigatran 10 and rivaroxaban 11 periprocedurally for AF ablation is safe. However, the sample sizes in these studies were small for the purposes of studying infrequent complications. These were also selected patients in the controlled environment of randomized trials, with procedures being performed in world leading centers.
In this study, we report our experience of CA for AF on uninterrupted DOACs in a large real-world registry. We compared patients who underwent AF ablation on uninterrupted DOACs to those on uninterrupted warfarin in a case-control study to determine the safety and efficacy of both approaches.
METHODS

Study design
This was a retrospective, single-center, case-control study evaluating the efficacy and safety of different anticoagulation regimens in the setting of CA for AF. Consecutive patients over 28 months were included.
Patients on DOACs were compared to those anticoagulated with warfarin. Prior to the procedure, all patients gave written informed consent. All data presented were prospectively recorded in our departmental AF ablation registry.
Study patients
All patients undergoing CA for AF and anticoagulated with either a DOAC (rivaroxaban, apixaban, or dabigatran) or warfarin were included in the study. Edoxaban was not deliberately excluded but was not used for any patients during the study period. A transesophageal echocardiogram (TEE) was performed prior to the procedure in all patients except those with paroxysmal AF who had been therapeutically anticoagulated for at least 3 weeks and were deemed not to be exceptionally high risk of stroke (e.g., hypertrophic cardiomyopathy, or previous stroke on anticoagulation). Those with left atrial appendage (LAA) thrombus did not go on to have an ablation. Patients on uninterrupted DOACs were compared to those on uninterrupted warfarin.
Anticoagulation regime
An uninterrupted anticoagulation regime was adopted for all patients regardless of whether they were on a DOAC or warfarin. All patients were anticoagulated for at least 3 weeks prior to the ablation. For those taking warfarin, the target therapeutic INR was 2-3. INR was checked on a weekly basis prior to the procedure and on the day of the procedure.
Patients taking a twice-daily DOAC took their usual dose in the morning and the evening of the procedure. Patients taking a once-daily DOAC were encouraged to take this in the evening for the week prior to the procedure, then take this the night before and the evening immediately after their procedure. However, patients still taking their dose in the morning continued this as usual.
Need for procedure cancellations because of anticoagulation issues (supratherapeutic INR on the day of the procedure, subtherapeutic INR in the three previous weeks, or omitted DOAC doses) were compared. 
CA procedure
Procedures were carried out either under intravenous moderate sedation or a general anesthetic. 
Management of bleeding complications
Follow-up
Patients were kept in overnight and discharged home the following day. They were reviewed in clinic at 3 months postablation. Additional 
Endpoints
The primary endpoint of the study was a composite of death or any major bleeding or embolic complications over the follow-up period of at least 3 months. All complications were prospectively recorded in the nationally mandated institutional registry. All complications were reviewed to allow the application of a rigorous consensus definition compatible with guidelines. 5, 12 Complications were considered to be major if they resulted in permanent injury or death, required intervention for treatment, or resulted in prolonged hospitalization for ≥ 48 hours. This included death, any thromboembolic event, tamponade, and atrioesophageal fistula.
A stroke was defined as a sudden focal neurological deficit of presumed cerebrovascular etiology lasting for > 24 hours, not due to another identifiable cause and confirmed by computed tomography or magnetic resonance imaging of the brain. If symptoms were short lasting (< 24 hours) and no evidence of necrosis was found on brain imaging, the event was considered to be a transient ischemic attack (TIA). A systemic embolic event was defined as an abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of another likely mechanism (e.g., atherosclerosis, instrumentation, or trauma). A pulmonary embolism was diagnosed when dyspnea or other suggestive clinical presentation was accompanied by radiological confirmation of a new pulmonary perfusion or intraluminal defect.
Bleeding complications considered to be major complications included cardiac tamponade, massive hemoptysis, hemothorax, retroperitoneal bleeding, or any other bleeding considered to be life threatening, necessitating intervention (including thrombin injection, placement of a drain, or surgery), transfusion, or causing prolongation of hospitalization or reattendance to hospital following discharge.
Bleeding complications such as groin hematomas not meeting these criteria were considered minor complications. Phrenic nerve palsy was considered a major complication if it persisted at the end of the procedure, but if transient and fully resolved by the end of the case was considered a minor complication.
Statistical analyses
Data were analyzed on an intention-to-treat basis. All analyses were carried out using SAS version 9.3 statistical software (SAS Institute, Cary, NC, USA). Continuous data were presented as mean ± standard deviation or median (range) if not normally dis- tributed. Categorical data were reported as a percentage. Continuous data were compared using unpaired t-test (if normally distributed) and Mann-Whitney U test if not normally distributed. Categorical data were compared using 2 test.
Multivariate analyses were carried out using binary logistic regression. Two analyses were performed. First, the impact of DOAC usage on the incidence of bleeding complications was assessed in both in a univariate model and in a multivariate model including persistent AF, cryoablation, and gender as binary variables and age as a continuous variable. The second analysis split the cohort into those taking DOACs and those taking warfarin. The multivariate analysis was then repeated for each group with the same four other factors (age, gender, whether AF was persistent, and type of ablation energy used, i.e., cryoor radiofrequency) to see if these factors rendered patients at high risk of bleeding with either DOACs or warfarin. A P-value of < 0.05 was considered significant.
RESULTS
Study patients
A total of 1,884 consecutive AF ablation procedures performed at a single institution over 28 months (May 2015-September 2017) were included. Note that 761 procedures (on 609 patients) were performed on uninterrupted warfarin (Warfarin group), and 1,123 procedures (900 patients) on uninterrupted DOAC (DOAC group). Of the DOAC group 64% of the ablations were on uninterrupted rivaroxaban, 32% on apixaban, and 4% on dabigatran. The two groups were well matched for clinical characteristics (Table 1) .
Procedural data
All procedures were performed by a consultant electrophysiologist.
Seventeen operators (consultants) at a single center performed these procedures. All patients received intravenous unfractionated heparin after transseptal puncture with a target ACT of 300-350 seconds.
There was no significant difference between the groups with respect to procedural data ( Table 2) .
During the study period, a further three patients had their procedure cancelled due the presence of a LAA thrombus. Two patients had been anticoagulated with rivaroxaban and the third with warfarin (with a therapeutic INR of > 2 for over 3 months). There were no missed doses in any of these patients. All patients had persistent AF with a CHA 2 DS 2 -VASc score of 3, 3, and 4, respectively.
Study endpoints 3.3.1 Primary endpoint-complications
There was no significant difference in the primary endpoint (a composite of death, thromboembolism, or major bleeding complications) Fluoroscopy time, min, mean ± SD 9.5 ± 9 9 ± 7 0.19
Note:
The procedural characteristics of the DOAC (n = 1,123) and Warfarin (n = 761) groups are shown in this table. Data are reported as percentage or mean ± SD. AF = atrial fibrillation; DOAC = direct oral anticoagulant; SD = standard deviation. Of the tamponades that occurred, none were thought related to a steam pop, 16 of 27 were thought to be related to transseptal puncture (11/19 in the DOAC group compared to 5/8 in the Warfarin group; P = 1.00), and 11 of 27 were thought not to be related to the transseptal puncture (8/19 in the DOAC group compared to 3/8 in the Warfarin group; P = 1.00). Pericardial fluid drained was not significantly different in the two groups (DOAC vs Warfarin; 710 ± 748 mL vs 532 ± 113 mL; P = 0.51).
Two patients in the DOAC
Only a small proportion of patients required blood transfusion postprocedure (n = 3, 0.3% in the DOAC group and n = 1, 0.1% in the Warfarin group; P = 0.36). All of them had suffered blood loss as a result of cardiac tamponade.
Ongoing hemoptysis for 4 days postablation was seen in one patient in the Warfarin group. There was no evidence of pulmonary vein stenosis on imaging. This was attributed to interstitial lung disease due to amiodarone and recovered with conservative management alone.
Multivariate analysis of factors impacting bleeding risk
A univariate analysis did not show any significant association between the use of DOAC and bleeding events (hazard ratio 
Other major complications
One patient in the DOAC group presented with a pharyngeal perforation 2 days postprocedure. This was likely due to the TEE and was man- and 6 months' follow-up, respectively (Table 3) .
Secondary endpoint-procedural success
Acute ablation success (defined as restoration of sinus rhythm and confirmed pulmonary vein isolation) was similar in both groups (DOAC vs 
Procedure cancellations
No procedures in the DOAC group were cancelled due to anticoagulation issues. However, 23 patients who were anticoagulated with warfarin had their procedure cancelled due to an INR out of the therapeutic range (DOAC vs Warfarin; 0 vs 3.02%, P < 0.001).
DISCUSSION
In the present study, we report our experience of performing CA for AF on uninterrupted DOACs in a large unselected real-world registry.
In over a thousand patients ablated on uninterrupted DOACs, this approach was found to be safe and effective with no increased risk of periprocedural bleeding or thromboembolism compared to uninterrupted warfarin. Moreover, there was no significant difference in the overall complication rate between the DOAC and Warfarin groups. The preliminary data from registry studies on patients undergoing AF ablation on DOACs show the safety and efficacy of this approach.
However, in all of these studies DOACs were discontinued for 6-48 hours prior to the procedure and restarted 6-24 hours after hemostasis was achieved postablation. 9, 10, 18, 19 In some studies, bridging with LMWH was also used. This is therefore the largest registry examining AF ablation on DOACs and is also the only one in which DOACs were genuinely uninterrupted. Other registry studies have reported a significantly higher risk of bleeding with the use of a DOAC (dabigatran) periprocedurally when compared to warfarin. 6 This study reported a generally high risk of both thromboembolic complications and bleeding risk associated with AF ablation (dabigatran vs warfarin;
16% vs 6% and 6% vs 1%). 6 The higher bleeding risk was attributed to discontinuation of dabigatran on the morning of the procedure primary endpoint of major bleeding events after CA, the use of uninterrupted rivaroxaban was feasible and comparable to those for uninterrupted VKA therapy. 10 The RE-CIRCUIT trial investigated the safety of uninterrupted dabigatran versus VKA in patients undergoing AF ablation. The incidence of major bleeding was found to be lower in patients with uninterrupted dabigatran. 17 However, these trials were under strict RCT conditions, had a smaller sample size than this registry, and were limited to single with LMWH is associated with potentially increased bleeding risks 6 and is an expensive and cumbersome approach. There may therefore be a similar danger with this approach for DOACs.
We used a system of selective TEE to screen for LAA thrombus.
Even with continuous oral anticoagulation (warfarin or DOAC) a small number of LAA thrombi were identified. The selective system of TEE described presumably identified all LAA thrombi as there were no strokes in the cohort. This suggests that TEE is not essential to rule this out in all patients, but that some system of screening ought to be considered (whether with TEE, intracardiac echo, or computed tomography of left atrium).
STUDY LIMITATIONS
This is a retrospective, observational, and nonrandomized study. All procedures were performed at a single high-volume arrhythmia center with expertise in performing AF ablations. The outcomes may be influenced by operator experience.
Although there was no signal for concern regarding any particular DOAC, given the low numbers of events it was not possible to assess the association of individual DOACs with outcomes in a multivariate model. Furthermore, no patients in this cohort were taking edoxaban.
Despite the large number of patients included, only two patients required the reversal of anticoagulation with Octaplex (both for rivaroxaban). It should be noted that this is not a specific reversal agent (reversal agents are not available for factor Xa inhibitors at the time of writing). This study was therefore still underpowered to fully assess the management of serious bleeding complications, which require reversal of anticoagulation for DOACs.
CONCLUSIONS
This study shows that CA for AF can be performed safely and effectively in patients anticoagulated with uninterrupted DOACs in addition to systemic heparinization (with therapeutic ACT). The overall complication rate including bleeding risk was not increased with this approach compared to uninterrupted warfarin. Taken together with the results of recent RCTs examining this practice, it may be appropriate to revise current guidelines, which recommend periprocedural interruption of DOACs. Performing AF ablation on uninterrupted DOACs led to fewer cancellations than with uninterrupted warfarin, suggesting this approach may also be more practical.
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